Tidewave Bio

Tidewave Bio is pioneering a novel approach to cell therapy for solid tumors, which represent 90% of cancers. The company's strategy is built on two pillars: TRANSFORM the cell therapy business model by reducing costs and complexity, and RESOLVE the technical limitations of current immunotherapies. Its platform combines an engineered, universal cell product derived from hematopoietic stem cells with a point-of-care system for rapid personalization, aiming to provide faster, more potent, and broadly accessible treatment. Founded in 2021 and led by industry veterans, the company is positioning itself to address a market opportunity estimated to be 10-100x larger than the current CAR-T market.

Universal, off-the-shelf engineered antigen-presenting cell platform derived from allogeneic hematopoietic stem cells. Combined with a point-of-care disposable system that personalizes the universal product in real-time using a patient's tumor biopsy.

Tidewave competes in the crowded solid tumor cell therapy arena, which includes companies developing autologous TILs, TCR-T therapies, and allogeneic NK or T-cell platforms. Its key differentiator is the combination of an allogeneic, universal cell product with real-time, point-of-care personalization, aiming to solve for both manufacturing scalability and patient-specific efficacy simultaneously—a unique but unproven approach.